Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Reexamination Certificate
2000-04-17
2003-09-23
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
C424S443000, C424S422000, C424S425000, C514S458000
Reexamination Certificate
active
06623752
ABSTRACT:
The invention relates to a patch or plaster for transdermal application of pergolide and its pharmaceutically harmless salts.
Pergolide (D-6-n-propyl-8&bgr;-methylmercaptomethylergoline) is a dopamine receptor coenzyme and is administered among other things as an anti-Parkinson agent (EP-A 0 003 667), for the treatment of addition caused by psycho-stimulants (EP-A 0 204 954), and for nicotine addiction (GB-A 2 204 240). Hereafter in the disclosure, “pergolide” will be referred to as “pergolid.”
Various orally administered formulations of pergolid are known from EP-A 0 003 667 and EP-A 0 527 835. The therapeutically effective daily dose is 0.01 to 20 mg.
Generally it can be said that the biological activity of drugs administered orally or intravenously is often unsatisfactory. The hepatic metabolism of the drug upon the first passage through the liver can lead to undesired concentrations and toxic by-products, or to the loss of or reduction of effect. Compared to oral administration, the transdermal administration of drugs or agents has various advantages. The drug supply can be better controlled over a longer time interval, whereby significant blood plasma fluctuation is avoided. In addition, the required therapeutic dosage can usually be distinctly reduced. Furthermore, a patch is often more preferred by the patient than one or more tablets to be taken daily.
In oral application, pergolid has a low bio-activity. Consequently, it is difficult to achieve a constant blood plasma level over a longer time period, so that three doses daily are required.
The object of the present invention is to provide a transdermal system for the systematic application of pergolid or one of its pharmaceutically harmless salts where the drawbacks of oral administration forms are avoided.
The object underlying the invention is now solved with a transdermal therapeutic system with an amount of pergolid or one of its pharmaceutically harmless salts.
The agent pergolid can be applied as a free pergolid base, pergolid mesylate and/or pergolid hydrochloride.
Pergolid or one of its pharmaceutically acceptable salts as the active agent can also be used in combination with one or more further known substances, particularly in two-fold or three-fold combinations. These further known agents can modify, enhance, synergize or alter the potency of the pergolid effect. For example, dopamine coenzymes can be provided.
Particularly suitable further agents include levodopa, carbidopa, selegeline, tracrine, physostingmine, galanthamine, 1-hydroxytacrine and/or chemical derivatives thereof, metabolites thereof and/or pharmaceutically acceptable salts thereof.
Suitable permeation promoters include singly and/or multi-valent aliphatic, cycloaliphatic and/or aromatic-aliphatic alcohols with up to 8 C atoms, for example ethanol, 12-propandiol, dexpanthenol and/or polyethylene glycol, alcohol/water mixtures: saturated and/or unsaturated fatty alcohols with 8 to 18 carbon atoms; saturated and/or unsaturated fatty acids with 8 to 18 carbon atoms; their esters; natural vitamin E; synthetic vitamin E; and/or vitamin E derivatives.
Since pergolid is light-sensitive to a certain extent, stabilizers can be employed, for example as is known from U.S. Pat. No. 5,114,948 or EF-B 0 314 387. Examples include polyvinylpyrrolidone, alpha-tocopherolsuccinate, propylgallate, methionine, cysteine and/or cysteine hydrochloride.
The transdermal therapeutic system according to the invention can be a patch, particularly with an impermeable cover layer and removable protection layer, especially a matrix system or a membrane system.
The cover layer can be polyester, polypropylene, polyethylene or polyurethane, optionally provided with a metallisation or pigment. The removeable protection layer can be polyesters polypropylene or paper with a silicone and/or polyethylene coating.
The transdermal therapeutic system according to the invention may be a matrix patch with
an impermeable cover layer
a drug-containing self-adhesive matrix layer or a drug-containing matrix layer which is coated with an adhesive,
a removeable protection layer and
pergolid or one of its pharmaceutically acceptable salts as the active agent (drug),
optionally with further active agents and/or permeation promoters and/or stabilisers.
The matrix can be based on polyacrylate, silicone, polyisobutylene, butyl rubber, styrene/butadiene copolymer or styrene/isoprene copolymer. Such matrix materials common in the medical field are known in the prior art. Examples of acrylate adhesives include DuroTak adhesives.
A further embodiment of the invention relates to a membrane system including
an impermeable cover layer,
a drug-containing reservoir or a drug-containing reservoir layer,
a semi-permeable membrane,
a facultative adhesive layer,
a removeable protection layer and
pergolid or one of its pharmaceutically acceptable salts,
optionally, further active agents and/or permeation promoters, stabilisers, emulsifying agents, thickening agents and/or common membrane system or reservoir patch additives.
The drug-containing reservoir layer can thus be provided in an intermediate space formed between the covering layer and the membrane. The reservoir is filled with the active agents (drug) and facultative additives.
Inert polymers are suitable for the membrane, particularly on the basis of polypropylene, polyvinylacetate or silicone
When a membrane is provided, it can have the effect of controlling drug release depending on the pore size.
REFERENCES:
patent: 4797405 (1989-01-01), Conine et al.
patent: 5114948 (1992-05-01), Conine et al.
patent: 5378730 (1995-01-01), Lee et al.
patent: 5607691 (1997-03-01), Hale et al.
patent: 5656286 (1997-08-01), Miranda et al.
patent: 5738869 (1998-04-01), Fischer et al.
patent: 42 40 798 (1993-06-01), None
patent: 0 003 667 (1982-07-01), None
patent: 0 458 640 (1991-11-01), None
patent: 0 204 954 (1992-07-01), None
patent: 0 314 387 (1992-08-01), None
patent: 2 204 240 (1988-05-01), None
patent: WO 89/09599 (1989-10-01), None
patent: WO 91/00746 (1991-01-01), None
patent: WO 91/16885 (1991-11-01), None
patent: WO 96/04910 (1996-02-01), None
patent: WO 96/40139 (1996-12-01), None
Fischer Wilfried
Sendl-Lang Anna
Zeh-Herwerth Dagmar
Brooks & Kushman P.C.
Hexal AG
Page Thurman K.
Pulliam Amy E
LandOfFree
Patch for transdermal application for pergolid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Patch for transdermal application for pergolid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Patch for transdermal application for pergolid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3003381